-$1.35
-$0.11
bear -$1.35
base -$0.96
bull -$0.11
market price* $0.36
WHAT THE BUSINESS IS. Heron Therapeutics sells four hospital drugs in the United States. CINVANTI is an injectable form of aprepitant that prevents chemotherapy-induced nausea; at $42.3 million in the first half of 2026 it is still about 58% of sales. ZYNRELEF is a long-acting local anesthetic placed in the surgical wound ($21.3 million in the half, up 31%). APONVIE is aprepitant for post-operative nausea ($7.7 million, up 62%). SUSTOL is a nausea drug now in run-off ($1.1 million). Total product sales were $154.9 million in 2025 and $72.4 million in the first half of 2026, down 4.9%. WHAT THE BUSINESS HAS EARNED. Heron has not generated cash for its owners in any year on record. We measure what an owner can take out as operating cash flow, stripping out working-capital swings, minus the economic cost of stock pay and the capital spending needed to stay in business. On that measure the company consumed $174 to $229 million a year from 2016 to 2022 and $109 million in 2023. It then came close to breakeven: a $9 million outflow in 2024 and $6 million in 2025, or 6 and 4 cents a share. Measured before interest, which is how we value the business before its lenders, 2024 was about $4 million negative and 2025 was roughly breakeven. Our figures for 2021-2025 are slightly better than in our previous analysis. That is because we now strip out working-capital movements, mainly a $31 million inventory build in 2025 that the earlier figures treated as a cost. The first half of 2026 went backwards. Gross profit fell to $50.2 million from $57.8 million, the operating loss widened to $6.8 million, and on our measure the business consumed about $9 million before interest. Because no year has been positive, there is no normal earnings level to anchor on. The starting point is the 2024-2025 breakeven, and the question is whether the business can stay there as CINVANTI erodes. THE CINVANTI PROBLEM. In June 2026 the federal court in Delaware held invalid the asserted claims of two later CINVANTI patents in Heron's case against Azurity/Slayback. Days later the FDA approved Azurity's ready-to-use aprepitant injectable emulsion. Heron says it will appeal, and it has withdrawn its 2026 guidance because it cannot forecast generic timing. Separately, a December 2024 ruling upheld Heron's core patents (expiring September 2035) against Fresenius Kabi, which has appealed to the Federal Circuit. Mylan and Qilu have settled, with Mylan licensed to launch generic CINVANTI and APONVIE from June 1, 2032. Baxter's generic application is stayed until May 2028 unless the litigation resolves sooner. The second quarter already showed CINVANTI down 9.7%. CINVANTI carries the highest margin, so each $10 million of lost CINVANTI sales costs roughly $8 to $8.5 million of gross profit. THE DEBT. Heron owes Hercules Capital about $100 million on a secured working-capital facility after a $13.5 million paydown in August 2026. The facility costs Prime plus 1.95% with a 9.45% floor, plus 1% paid-in-kind interest, plus an end-of-term charge of up to 6.25%, and it matures September 1, 2030. Heron also owes about $37 million of 2031 convertible notes (5% cash or 7% paid-in-kind) convertible at $1.80, and $7.9 million of convertible preferred stock that ranks ahead of the common. Against this it holds about $29 million of cash after the paydown, of which we treat about $10 million as needed to run the business. Because the Hercules loan costs well above our 6% yardstick for four more years, we add about $15 million for its excess cost. Total claims ahead of the common come to roughly $148 million. Covenants were reset through 2027 in the August amendment, which indicates the old ones were at risk. The common shares also received a Nasdaq notice in June 2026 for trading below $1. The company has until December 22, 2026 to cure it, with a possible further 180 days, typically by a reverse split. THE CASES. Each case values the cash the business generates before paying lenders, then subtracts the roughly $148 million owed. Base case: Azurity's product takes share steadily, and CINVANTI falls from about $85 million a year to roughly $45 million by 2031, then to near zero after licensed generics arrive in 2032. ZYNRELEF and APONVIE are held at their current run-rate of about $61 million a year. We do not credit further growth: they are still building share in hospitals, and that growth is not yet a proven, self-funded process. Management cuts costs as oncology revenue falls, as it showed it could in 2023-2024, when cash operating costs fell by more than $50 million in one year. The business loses a few million a year through 2030, roughly breaks even around 2031, then loses its patent protection: APONVIE in 2032, ZYNRELEF between 2034 and 2035, CINVANTI's core patents in 2035. Nothing in the record shows a pipeline to replace them, so the story ends in the mid-2030s. The business is worth about minus $35 million, it owes about $148 million, and the shares are worth about minus $0.96. In this case the company owes roughly $180 million more than its business is worth. The Hercules maturity in 2030 could not be met from internal cash. Bear case: CINVANTI erodes the way injectable drugs typically do once a substitutable competitor arrives, losing 80-90% within two to three years. That could come from Azurity or from Fresenius winning its appeal. ZYNRELEF stalls. Cost cuts lag by a year. The business burns $30 to $38 million a year in 2027-2028, which exceeds the cash on hand. That would mean a covenant breach or a dilutive rescue on lender terms well before the 2030 maturity. The business is worth about minus $110 million, it owes about $148 million, and the shares are worth about minus $1.35. The company would owe about $260 million more than it is worth, and the common would be wiped out in a restructuring. Bull case: Heron wins on appeal, or Azurity's product proves not interchangeable at the pharmacy, so CINVANTI declines only gradually until 2032. ZYNRELEF and APONVIE keep growing at a slowing version of their recent 30-60% pace, toward roughly $110 million combined. Operating leverage then lifts cash generation before interest to $30 to $36 million a year at the 2031 peak, before the products reach the end of their patent lives in 2032-2035. The business is worth about $127 million, it owes about $148 million, and the shares are worth about minus $0.11. Even this good outcome leaves the lenders and preferred holders with essentially all the value. WHAT WOULD MAKE THIS WRONG. The cases cannot see a sale of the company: Heron announced a strategic review in August 2026, and an acquirer with an existing hospital sales force could strip out most of the operating costs. Nor do they assume growth in ZYNRELEF beyond what has been demonstrated. Our accounting choices: the $11.3 million loss on the 2025 debt exchange was non-cash and was added back, while stock compensation is charged as a cost every year. MARGIN-OF-SAFETY PRICE. We are not confident in the earnings level. The business has never produced owner cash, and its best year was breakeven, built on a product now facing an approved competitor. The worst plausible outcome is fast CINVANTI erosion while the secured lender controls the cash. That is a restructuring in which shareholders receive little or nothing, and the balance sheet, with a secured lender, a high-cost floating loan and a senior preferred, would not absorb it. Even if we are wrong in the company's favor on both CINVANTI and the newer products, the bull case still leaves nothing for the common after the debt. No price can be identified from which the cases reliably imply 20% a year, because none of the cases we can support gives the common positive value. The business pays nothing during the holding period, and its cash is going to its lenders. There is therefore no margin-of-safety price. The analysis would be revisited if a Federal Circuit ruling reinstates the CINVANTI patents, if a signed sale agreement fixes a price per share, or if the debt is cut materially without heavy dilution.